Related references
Note: Only part of the references are listed.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections
Chonghua Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model
C. Andrew DeRyke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps
Christine T. Ong et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2007)
Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients
Chonghua Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections
Joseph L. Kuti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics - Insights from the society of infectious diseases pharmacists
Thomas P. Lodise et al.
PHARMACOTHERAPY (2006)
Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients
XL Du et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Optimising dosing strategies of antibacterials utilising pharmacodynamic principles - Impact on the development of resistance
CA DeRyke et al.
DRUGS (2006)
Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa
VH Tam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Making the most of surveillance studies: summary of the OPTAMA Program
JL Kuti et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem
JE Conte et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Pharmacodynamics of antimicrobials for the empirical treatment of nosocmial pneumonia: A report from the OPTAMA Program
HK Sun et al.
CRITICAL CARE MEDICINE (2005)
Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: A report from the OPTAMA program
D Maglio et al.
CLINICAL THERAPEUTICS (2005)
Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers
WA Krueger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection
S Jaruratanasirikul et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment
JL Kuti et al.
CHEMOTHERAPY (2005)
Pharmacokinetics and pharmacodynamics of meropenern in febrile neutropenic patients with bacteremia
RE Ariano et al.
ANNALS OF PHARMACOTHERAPY (2005)
The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe
RG Masterton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model
D Maglio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation
BM Lomaestro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
GL Drusano
NATURE REVIEWS MICROBIOLOGY (2004)
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem
HA Mattoes et al.
CLINICAL THERAPEUTICS (2004)
Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in north America in 2002
JL Kuti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases
LR Moczygemba et al.
CLINICAL THERAPEUTICS (2004)
Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program:: the OPTAMA Program, South America 2002
CRV Kiffer et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem
JL Kuti et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection
S Jaruratanasirikul et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid
D Maglio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Share Paper
